[Hemorrhagic shock and fulminant hepatic failure associated with valproate].
Fulminant hepatic failure is an uncommon adverse effect of valproate treatment. Despite an increased use of valproate, since the drug was introduced in 1978, a decline in the number of reported cases has been observed. Here a case of hemorrhagic shock and fulminant hepatic failure in a patient treated with valproate is presented. We emphasize the diagnostic difficulties from the point of view of recognition of the clinical manifestations as well as the biochemical monitoring.
Fernandez-Fernandez
F J
FJ
Servicio de Medicina Interna, Universidad de Santiago de Compostela, La Coruña.
Garcia-Rego
J
J
Garcia-Jimenez
A
A
Sesma
P
P
D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D006501:Hepatic Encephalopathy / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D012771:Shock, Hemorrhagic / Q000139:chemically induced*; D013226:Status Epilepticus / Q000188:drug therapy*; D013997:Time Factors; D014635:Valproic Acid / Q000008:administration & dosage / Q000009:adverse effects*
D000927:Anticonvulsants; D014635:Valproic Acid
Shock hemorrágico e insuficiencia hepática fulminante asociada a valproato.